Summary & Overview
HCPCS Level II J0178: Injection, aflibercept, 1 mg
Headline: HCPCS Level II code J0178 covers intravitreal aflibercept (1 mg) injections used in ophthalmic care.
Lead: HCPCS Level II code J0178 denotes the injectable agent aflibercept, billed per 1 mg, and is used in intravitreal ophthalmology procedures nationwide. This code is central to claims for pharmacologic treatment of retinal conditions where aflibercept is indicated.
What the code represents and why it matters: HCPCS Level II code J0178 identifies the drug component of intravitreal therapy and separates the pharmaceutical supply from procedural billing. Accurate use of this code affects claim adjudication, inventory tracking, and payment for ophthalmic injectable therapies across outpatient settings.
Key payers covered: The analysis addresses coverage and billing context for Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
Overview of content: Readers will find an explanation of the clinical and billing context for J0178, common service settings, common modifier usage and billing pairings, and how the drug line interacts with the intravitreal injection procedure. The publication also outlines documentation elements, typical claim composition, and potential administrative considerations for accurate submission.
Audience takeaways: Clinicians, billing staff, and administrators will gain a concise reference for billing the drug component of intravitreal aflibercept, learn which payers are covered in the review, and identify where input data is missing for deeper benchmarking or state-specific policy details.
Data notes: Data not available in the input for service-line financial benchmarks and state-specific policy updates.
Billing Code Overview
HCPCS Level II code J0178 represents the medication aflibercept, billed per 1 mg unit for injection. The service involves administration of this ophthalmic pharmaceutical agent for intravitreal use in eye care.
Service type: Ophthalmology — intravitreal injection of a pharmaceutical agent
Typical site of service: Physician office or ambulatory surgical center
Clinical & Coding Specifications
Clinical Context
A 67-year-old patient with diabetes presents to an ophthalmology clinic for treatment of diabetic macular edema. The ophthalmologist performs an intravitreal injection procedure in a procedure room at a physician office or an ambulatory surgical center. The service involves preparation and administration of the antineovascular agent aflibercept (HCPCS Level II code J0178) into the vitreous cavity of the affected eye. Billing includes the HCPCS Level II drug code J0178 for aflibercept, and the intravitreal injection procedure is reported separately with 67028. Laterality is indicated with LT or RT as appropriate; if no drug is administered and none discarded, modifier JZ is applied.
Coding Specifications
-
Modifiers:
-
JZ: Zero drug amount discarded/not administered to any patient. Use when no portion of the drug vial or syringe is wasted or discarded and no dose was administered to any patient. -
LT/RT: Left or Right side. Use to indicate ocular laterality for the intravitreal injection when required by payer policy. -
Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
207W00000X | Ophthalmology |
Related Diagnoses
-
E08.311— Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edemaThis diagnosis indicates diabetic macular edema, a primary indication for intravitreal aflibercept (
J0178), and supports medical necessity for the injection procedure. -
E08.319— Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edemaThis diagnosis documents diabetic retinopathy without macular edema; it may be present in the same patient and is relevant to ophthalmologic evaluation and treatment planning for intravitreal therapy.
Related Codes
67028: Intravitreal injection of a pharmacologic agent (separate procedure). This procedural code describes the ocular injection service performed by the ophthalmologist and is billed separately from the HCPCS Level II drug codeJ0178. These two codes are commonly reported together in the clinical workflow for intravitreal administration of aflibercept. Data not available in the input for additional related codes.
National Reimbursement Benchmarks
National commercial mean rates for HCPCS Level II code J0178 are higher on average than Medicare for the commercial composite (BUCA) benchmark: BUCA’s mean of $829.41 compares with Medicare (Data not available in the input.), while Aetna and UnitedHealthcare report the highest commercial means at $904.99 and $872.29, respectively.
Rate dispersion varies notably across payers. Cigna Health shows the tightest distribution with P75–P25 equal to $0.00 (both at $772), followed by UnitedHealthcare (difference $47.00) and Blue Cross Blue Shield (difference $76.00). Aetna and BUCA show wider dispersion at $77.33 and $69.00, respectively. The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.